The European Hematology Affiliation (EHA) Hybrid Congress is the biggest gathering of the hematology subject in
“I’m delighted to showcase the power and progress of Ascentage Pharma in hematology at this yr’s congress, particularly the therapeutic potential and medical worth of its drug candidates in persistent myeloid leukemia (CML),
The 5 research to be introduced at EHA 2024 are as follows:
Olverembatinib Overcomes Ponatinib and Asciminib Resistance in Sufferers (Pts) with Closely Pretreated Power Myeloid Leukemia (CML) and Philadelphia-Optimistic Acute Lymphoblastic Leukemia (Ph º ALL)
¢ Summary#: P722
¢ Presentation Kind: Poster presentation
¢ Matter: Power myeloid leukemia “ Medical
¢ Date & Time:
¢ Presenting Writer: Dr. Elias Jabbour, The College of Texas MD Anderson Most cancers Heart
Mixture of Third Technology TKI Olverembatinib and Chemotherapy or Blinatumomab for New Recognized Grownup Ph+ ALL Sufferers
¢ Summary#: P427
¢ Presentation Kind: Poster presentation
¢ Matter: Acute lymphoblastic leukemia “ Medical
¢ Date & Time:
¢ Presenting Writer: Junjie Chen, Nanfang Hospital, Southern Medical College
Affected person Reported Outcomes in Adults with TKI-Resistant Power Myeloid Leukemia Receiving Olverembatinib-Remedy
¢ Summary#: P1862
¢ Presentation Kind: e-Poster presentation
¢ Matter: Power myeloid leukemia “ Medical
¢ Date & Time: Friday June 14, 2024,
¢ Presenting Writer: Lu Yu, Peking College Folks’s Hospital
Lisaftoclax (APG-2575) Mixed with Novel Therapeutic Regimens in Sufferers (Pts) with Relapsed or Refractory (R/R) A number of Myeloma (MM) or Immunoglobulin Gentle-Chain (AL) Amyloidosis
¢ Summary#: P917
¢ Presentation Kind: Poster presentation
¢ Matter: Myeloma and different monoclonal gammopathies “ Medical
¢ Date & Time:
¢ Presenting Writer: Dr. Sikander Ailawadhi, Mayo Clinic Florida
Embryonic Ectoderm Growth (EED) Inhibitor APG-5918 Improves Power Kidney Illness- (CKD)-Induced Hemoglobin (HB) Insufficiency in Preclinical Fashions of Anemia
¢ Summary#: P1550
¢ Presentation Kind: Poster presentation
¢ Matter: Enzymopathies, membranopathies and different anemias
¢ Date & Time:
¢ Presenting Writer: Dr. Eric Liang, Ascentage Pharma Group Inc.
About Ascentage Pharma
Ascentage Pharma (6855.HK) is a globally targeted biopharmaceutical firm engaged in growing novel therapies for cancers, persistent hepatitis B, and age-related ailments. On
Ascentage Pharma focuses on growing therapeutics that inhibit protein-protein interactions to revive apoptosis, or programmed cell loss of life. The corporate has constructed a pipeline of 9 medical drug candidates, together with novel, extremely potent Bcl-2, and twin Bcl-2/Bcl-xL inhibitors, in addition to candidates aimed toward IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs). Ascentage Pharma can also be the one firm on the earth with lively medical packages concentrating on all three identified lessons of key apoptosis regulators. The corporate is conducting greater than 40 Part I/II medical trials, together with 5 world registrational section III research, within the US,
Olverembatinib, the corporate’s core drug candidate developed for the therapy of drug-resistant persistent myeloid leukemia (CML) and the corporate’s first authorized product, has been granted Precedence Overview Designations and Breakthrough Remedy Designations by the Heart for Drug Analysis (CDE) of China Nationwide Medical Merchandise Administration (NMPA). To this point, the drug had been included into the
Leveraging its sturdy R&D capabilities, Ascentage Pharma has constructed a portfolio of worldwide mental property rights and entered into world partnerships with quite a few famend biotechnology and pharmaceutical corporations and analysis institutes resembling UNITY Biotechnology, MD Anderson Most cancers Heart, Mayo Clinic, Dana-Farber Most cancers Institute, MSD, and AstraZeneca (NASDAQ:). The corporate has constructed a gifted group with world expertise within the discovery and improvement of revolutionary medicine and is organising its world-class business manufacturing and Gross sales & Advertising groups. One pivotal intention of Ascentage Pharma is to constantly strengthen its R&D capabilities and speed up its medical improvement packages, to be able to fulfil its mission of addressing unmet medical wants in
Ahead-Wanting Statements
The forward-looking statements made on this article relate solely to the occasions or info as of the date on which the statements are made on this article. Besides as required by regulation, Ascentage Pharma undertakes no obligation to replace or revise publicly any forward-looking statements, whether or not on account of new info, future occasions, or in any other case, after the date on which the statements are made or to mirror the prevalence of unanticipated occasions. It’s best to learn this text fully and with the understanding that our precise future outcomes or efficiency could also be materially totally different from what we count on. On this article, statements of, or references to, our intentions or these of any of our Administrators or our Firm are made as of the date of this text. Any of those intentions might alter in mild of future improvement.